EAJF Stock Overview
A biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ValiRx plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.019 |
| 52 Week High | UK£0.15 |
| 52 Week Low | UK£0.01 |
| Beta | 0.54 |
| 11 Month Change | 21.88% |
| 3 Month Change | -11.36% |
| 1 Year Change | -83.88% |
| 33 Year Change | -95.00% |
| 5 Year Change | -92.20% |
| Change since IPO | -99.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| EAJF | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 69.6% | -0.7% | -0.02% |
| 1Y | -83.9% | -17.2% | 8.2% |
Return vs Industry: EAJF underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: EAJF underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| EAJF volatility | |
|---|---|
| EAJF Average Weekly Movement | 42.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EAJF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EAJF's weekly volatility has increased from 28% to 43% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 16 | n/a | www.valirx.com |
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells.
ValiRx plc Fundamentals Summary
| EAJF fundamental statistics | |
|---|---|
| Market cap | €2.67m |
| Earnings (TTM) | -€2.37m |
| Revenue (TTM) | €11.55k |
230.9x
P/S Ratio-1.1x
P/E RatioIs EAJF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EAJF income statement (TTM) | |
|---|---|
| Revenue | UK£9.60k |
| Cost of Revenue | UK£1.44k |
| Gross Profit | UK£8.16k |
| Other Expenses | UK£1.98m |
| Earnings | -UK£1.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 85.00% |
| Net Profit Margin | -20,554.01% |
| Debt/Equity Ratio | 0.5% |
How did EAJF perform over the long term?
See historical performance and comparison